# Arrowhead Pharmaceuticals Inc. (ARWR) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $86.34, market value $12.2 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Arrowhead Pharmaceuticals Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 18.2×**. Each dollar of revenue is priced at 18.2×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 26.2×**. The shares trade at 26.2× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -0.6%** (5-yr avg -7.5%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -33.8%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -0.2%**. The company reported a net loss over the last twelve months.
- **Return on equity: -0.3%**. Return on equity is negative because earnings are negative.
- **Return on assets: -23.1%**. Each dollar of assets produces -23.1% of profit.

## Growth
- **EPS growth (1 yr): 99.8%**. Earnings per share rose 99.8%.

## Financial health
- **Current ratio: 4.86** (quick 4.86). Current assets cover the next year's liabilities 4.86 times.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Arrowhead Pharmaceuticals Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (11 analysts). 11 analysts cover Arrowhead Pharmaceuticals Inc.; the consensus is strong_buy, with an average price target of $110.18 (+28% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 208.4%** (YTD 30.0%, 3-mo 18.1%). The shares are up 208.4% over twelve months including dividends.
- **From 52-week high: -9.6%** (218.0% above the low). Trading 10% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 52**. An RSI of 52 is neutral.
- **Beta (1 yr): 1.47** (volatility 61%). Beta of 1.47 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ARWR · Page: https://foliofundamentals.com/stocks/arwr

Not investment advice.